drugset / Trial / NCT04531423

PKC as Serum Biomarkers for Depression

NCT04531423

Unknown 100 enrolled Shanghai Mental Health Center
RandomizedParallel-groupSingle-blindTreatment

Summary

Inflammation that is mediated by microglia activation plays an important role in the pathogenesis of depression. Microglia activation can lead to an increase in the levels of proinflammatory cytokines, including TNF-α, which leads to neuronal apoptosis in the specific neural circuits of some brain regions, abnormal cognition, and treatment-resistant depression (TRD). Protein kinase C (PKC) is a key regulator of the microglia activation process. The investigators assume that the abnormality in PKC might be the serum biomarkers of depression.

Timeline

Start
2020-10-01
Primary completion
2022-09-30
Completion
2022-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Golimumab Monoclonal antibody 50 mg